1,2,4-Triazole-Based First-in-Class Non-Nucleoside Inhibitors of the Bacterial Enzyme MraY

Area of Science:

• Medicinal Chemistry
• Microbiology
• Drug Discovery

Background:

• MraY is a crucial enzyme in bacterial cell wall peptidoglycan synthesis.
• MraY is a promising drug target, but existing nucleoside inhibitors have limitations.
• Developing novel, non-nucleoside inhibitors is essential for new antibacterial strategies.

Purpose of the Study:

• To discover and develop first-in-class, non-nucleoside small molecule inhibitors of MraY.
• To utilize a structure-based drug design approach for MraY inhibitor development.
• To evaluate the antibacterial activity of novel MraY inhibitors against critical pathogens.

Main Methods:

• Structure-based drug design was employed to identify MraY inhibitors.
• 1,2,4-triazole derivatives were synthesized and optimized.
• In vitro enzyme inhibition assays (IC50 determination) were performed.
• Molecular docking studies were conducted to understand binding interactions.
• Broad-spectrum antibacterial activity was assessed against various bacterial strains.

Main Results:

• A novel series of non-nucleoside MraY inhibitors based on 1,2,4-triazoles was discovered.
• The initial hit compound (1) showed an IC50 of 171 μM, refined to compound 12a with an IC50 of 25 μM against MraY from Staphylococcus aureus (MraY_SA).
• Molecular docking provided insights into structure-activity relationships.
• The compounds demonstrated broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria, including MRSA, VRE, Acinetobacter baumannii, and Mycobacterium tuberculosis.

Conclusions:

• Novel non-nucleoside MraY inhibitors were successfully developed using a structure-based approach.
• These compounds represent a promising proof-of-concept for next-generation antibacterial agents targeting MraY.
• The findings support the potential of non-nucleoside MraY inhibitors in combating drug-resistant bacterial infections.